Search clinical trials for: GSK573719 125

Total 2434 results

GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
GlaxoSmithKline

Completed

Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
GlaxoSmithKline

Completed

A Study of GSK573719 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Pulmonary Disease, Chronic Obstructive

Czechia, Hungary
GlaxoSmithKline

Completed

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Hungary, Slovakia
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719 in Japanese (AC4115361)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Ukraine, Germany, Peru, Poland, France, Romania, Italy, Mexico
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

QTc Study GSK573719+GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
Penn State University

Terminated

The Role of Satiety in the Effect of Portion Size on Intake

Feeding Behavior

United States
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, United States, Bulgaria, Estonia, United Kingdom
GlaxoSmithKline

Completed

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Germany
Pauls Stradins Clinical University Hospital

Recruiting

Latvian Early Atherosclerosis Registry

Coronary Artery Disease | Atherosclerosis, Coronary

Latvia
Ake Norberg

Completed

A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA

Healthy | SIRS

Sweden
GlaxoSmithKline

Completed

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Germany, Japan, United States
Queen's University
GlaxoSmithKline

Completed

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

COPD

Canada
GlaxoSmithKline

Completed

A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

Pulmonary Disease, Chronic Obstructive

Netherlands
Biodel

Completed

Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration

Diabetes Mellitus
Karolinska Institutet
Karolinska University Hospital; Region Stockholm

Completed

Albumin Kinetics in Generalized Inflammation

Major Abdominal Surgery

Sweden
Neuropore Therapies Inc.
Celerion

Completed

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

Healthy Volunteers

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States, Canada
McGill University

Recruiting

DOvEE - Diagnosing Ovarian & Endometrial Cancer Early (DOvEE)

Ovarian Neoplasms

Canada
GlaxoSmithKline

Withdrawn

Aura Adolescent PK Study GSK2829332

Asthma
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects (DB2113208)

Pulmonary Disease, Chronic Obstructive

Australia
Ain Shams Maternity Hospital

Unknown

CA-125 and Severity of Pre-Eclampsia

Pre-Eclampsia
Pain Therapeutics
National Institute on Aging (NIA)

Completed

A Safety Study of PTI-125 in Healthy Volunteers

Alzheimer Disease | Alzheimer Disease, Early Onset

United States
Cassava Sciences, Inc.

Enrolling by invitation

Open-label Extension for Phase 3 Clinical Trials of Simufilam

Alzheimer Disease

United States, Canada, Puerto Rico
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Homoarginine Supplementation in Patients After Stroke (HiS)

Deficiency; Diet

Germany
Pain Therapeutics
National Institute on Aging (NIA)

Completed

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

Alzheimer Disease

United States
Shanghai Institute of Hypertension

Recruiting

Home Blood Pressure Intervention in the Community Trial

Home Blood Pressure

China
Boston Scientific Corporation
EKOS Corporation

Withdrawn

Registry Study to Evaluate the Performance and Safety of Roxwood Medical Catheters in Arteries of Participants With a Stenotic Lesion or Chronic Total Occlusion (CTO)

Coronary Artery Disease | Atherosclerosis | Peripheral Artery Disease | Chronic Total Occlusion

United States
GlaxoSmithKline

Completed

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma (ILA115938)

Asthma

Argentina, Russian Federation, United States, Chile, Thailand
Xuzhou Central Hospital

Enrolling by invitation

I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma

Hilar Cholangiocarcinoma

China
E-DA Hospital

Unknown

The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring

Lung Cancer

Taiwan
Unither Pharmaceuticals, France
Raptim Research

Completed

Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)

Acute Pain

India
Napo Pharmaceuticals, Inc.

Active, not recruiting

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy (OnTARGET)

Adult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related Diarrhea

United States, Taiwan, Georgia, Serbia, Argentina
4D Molecular Therapeutics

Active, not recruiting

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

X-Linked Retinitis Pigmentosa

United States
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; M.D. Anderson Cancer Center

Completed

A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

Ovarian Cancer

United States
University of Missouri-Columbia
Medtronic

Completed

Incisional Vacuum Assisted Closure (IVAC) Device and Its Effect on Implanted Bone Morphogenic Protein (BMP-2)

Fractures, Closed

United States
King's College Hospital NHS Trust
King's College London

Completed

Glycaemic Response to Oral Nutrition Support During Haemodialysis (GRO-HD)

Diabetes | Chronic Kidney Disease | End Stage Renal Failure on Dialysis

United Kingdom
Odense University Hospital

Completed

Antithyroid Drugs During Radioiodine Therapy

Graves Disease | Toxic Nodular Goitre

Denmark
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of

Search clinical trials for: GSK573719 125

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations